Another important open question is whether tumor heterogeneity, a key aspect limiting the effectiveness of targeted therapies, is relevant in the case of K-RAS dependency, and therefore if a small percentage of K-RAS-independent cells might co-exist in the bulk of dependent tumor cells, a circumstance that could potentially limit the efficacy of any targeted therapies. The gene discussed is KRAS; the disease is neoplasm.